Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1, Open-Label, Single-Ascending Dose, Parallel Group Study to Determine the Pharmacokinetics, Safety, and Tolerability of ATRS-2002 Administered Subcutaneously in Healthy Adult Males

Next Previous
Trial Profile

Phase 1, Open-Label, Single-Ascending Dose, Parallel Group Study to Determine the Pharmacokinetics, Safety, and Tolerability of ATRS-2002 Administered Subcutaneously in Healthy Adult Males

Status: Withdrawn prior to enrolment
Phase of Trial: Phase I

Latest Information Update: 02 May 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abiraterone acetate (Primary) ; Abiraterone acetate
  • Indications Prostate cancer
  • Focus Pharmacodynamics; Pharmacokinetics

Most Recent Events

  • 26 Apr 2023 Status changed from not yet recruiting to withdrawn prior to enrolment because no participants were enrolled.
  • 19 Apr 2022 Planned End Date changed from 28 Dec 2021 to 1 Dec 2023.
  • 19 Apr 2022 Planned primary completion date changed from 10 Nov 2021 to 1 Sep 2023.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top